Search for: "Daubert v. Merrell Dow Pharmaceuticals, Inc."
Results 101 - 120
of 202
Sorted by Relevance
|
Sort by Date
29 Jan 2022, 6:24 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), Fed.Rules, Evid.Rules 104(a), 702. [read post]
15 May 2014, 9:36 am
Breg Inc., 613 F.3d 1329, 1342 (11th Cir. 2010); see also Norris v. [read post]
17 Jan 2014, 8:27 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
17 Mar 2014, 6:57 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
22 Feb 2011, 7:27 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), in analyzing the expert presentations relating to the Rule 23 requirements, Plaintiffs contend that the Ninth Circuit found this to be no abuse of discretion, and that it did not matter because the district court judge was "guided by Daubert," concluded that the expert opinions were "based on valid principles," and were "sufficiently probative" of the Rule 23 requirements. [read post]
27 May 2010, 3:40 pm
”Merrell Dow Pharmaceuticals, Inc. v. [read post]
4 Mar 2012, 9:02 am
Merrill Dow Pharmaceuticals, Inc., 874 F.2d 307, 311-12 (5th Cir. 1989)(“Fortunately, we do not have to resolve any of the above questions [as to bias and confounding], since the studies presented to us incorporate the possibility of these factors by the use of a confidence interval. [read post]
17 Jan 2014, 8:27 pm
Merrell Dow Pharmaceuticals, Inc., the United States Supreme Court held for the first time that, to be admissible, scientific evidence must be both scientifically valid and properly applicable to the facts at issue in the case. [read post]
31 Dec 2009, 2:34 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), and its federal and state progeny. [read post]
25 Apr 2015, 11:03 am
The first edition of the Reference Manual on Scientific Evidence [Manual] was published in 1994, a year after the Supreme Court delivered its opinion in Daubert. [read post]
14 Jun 2012, 7:27 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed. 2d 469 (1993). [read post]
17 Oct 2015, 5:29 am
” Earp v. [read post]
13 Jun 2017, 4:00 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993), where the Supreme Court ruled that, under the federal evidence rules, “the trial judge must ensure that any and all scientific testimony or evidence admitted is not only relevant, but reliable” in light of several factors enumerated by the Court. [read post]
25 Jan 2012, 6:42 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786 (1993), and discussed in Taylor v. [read post]
10 Jun 2013, 4:15 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
24 Dec 2012, 9:58 am
Merrell Dow Pharmaceuticals Inc., 509 U.S. 579 (1993), a case that has been superseded by subsequent cases and a revision to the operative statute, Rule 702. [read post]
3 Mar 2012, 5:36 pm
Merrell Dow Pharm., Inc., 911 F.2d 941, 958-9 (3d Cir. 1990) Daubert v. [read post]
18 Jan 2007, 10:48 am
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579 (1993). [read post]
21 Jun 2011, 4:52 am
Merrell Dow Pharmaceuticals, Inc., 509 U. [read post]
23 Jun 2010, 3:35 pm
Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S. [read post]